Nutex Health (NUTX) 10-Q 20 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Mar. 31, 2019shares
Document and Entity Information:
Entity Registrant Name	iGambit, Inc.
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Trading Symbol	igmb
Amendment Flag	false
Entity Central Index Key	0001479681
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding	387,553,890
Entity Filer Category	Non-accelerated Filer
Entity's Reporting Status Current	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets
Cash	$ 7,036	$ 369
Accounts receivable	10,366	14,871
Inventory	26,988	27,073
Total current assets	44,390	42,313
Other assets
Property and equipment, net	1,871	2,118
Intangilbe assets, net	2,398,048	2,572,015
Deposits	2,020	2,020
Total Assets	2,446,329	2,618,466
Current liabilities
Accounts payable and accrued expenses	570,331	480,270
Accrued interest on notes payable	20,939	32,265
Amounts due to related parties	139,753	145,367
Deferred revenue	5,467	9,192
Notes payable	52,500	52,500
Convertible notes payable, net	214,368	377,611
Derivative liability	219,516	288,242
Total current liabilities	1,222,874	1,385,447
Stockholders' equity
Preferred stock, $.001 par value; authorized - 100,000,000 shares; No shares issued and outstanding	0	0
Common stock, $.001 par value; authorized - 800,000,000 shares; 361,577,519 and 214,859,994 shares issued and 351,577,519 and 204,859,994 shares outstanding (net of treasury shares) as of March 31, 2019 and December 31, 2018, respectively	361,577	214,860
Additional paid-in capital	14,884,059	14,480,973
Accumulated deficit	(13,022,181)	(12,462,814)
Total stockholders' equity before Treasury stock	2,223,455	2,233,019
Less: Treasury stock; 10,000,000 shares, at cost	(1,000,000)	(1,000,000)
Total stockholders' equity	1,223,455	1,233,019
Liabilities and equity	$ 2,446,329	$ 2,618,466

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, par value	$ .001	$ .001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ .001	$ .001
Common stock, shares authorized	800,000,000	800,000,000
Common stock, shares issued	361,577,519	214,859,994
Common stock, shares outstanding	351,577,519	204,859,994
Treasury stock	10,000,000	10,000,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Sales	$ 5,325	$ 4,192
Cost of Sales	8,207	7,930
Gross profit (loss)	(2,882)	(3,738)
Operating Expenses
General and Administrative Expense	190,264	234,264
Amortization	173,967	173,967
Total operating expenses	364,231	408,231
Loss from operations	(367,113)	(411,969)
Other income (expenses)
Change in fair value of derivative liability	(53,163)	(118,101)
Loss on extinguishment of debt	(5,838)	(63,699)
Interest Expense	(133,253)	(16,264)
Total other income (expenses)	(192,254)	(198,064)
Net loss	$ (559,367)	$ (610,033)
Basic and fully diluted loss per common share:
Net loss per common share	$ 0	$ (.01)
Weighted average common shares outstanding - basic and fully diluted	286,206,039	121,245,294

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Treasury Stock	Total
Stockholders' Equity, beginning of period, Value at Dec. 31, 2017	$ 126,196	$ 12,891,348	$ (9,648,569)	$ (1,000,000)	$ 2,368,975
Stockholders' Equity, beginning of period, Shares at Dec. 31, 2017	126,196,571
Common stock issued for cash, Value	$ 750	14,250			15,000
Common stock issued for cash, Shares	750,000
Notes payable and accrued interest converted to common stock, Value	$ 5,345	342,758			348,103
Notes payable and accrued interest converted to common stock, Shares	5,344,180
Net loss			(610,033)		(610,033)
Stockholders' Equity, end of period, Value at Mar. 31, 2018	$ 132,291	13,248,356	(10,258,602)	(1,000,000)	2,122,045
Stockholders' Equity, end of period, Shares at Mar. 31, 2018	132,290,751
Stockholders' Equity, beginning of period, Value at Dec. 31, 2018	$ 214,860	14,480,973	(12,462,814)	(1,000,000)	1,233,019
Stockholders' Equity, beginning of period, Shares at Dec. 31, 2018	214,859,994
Compensation for vested stock options		1,025			1,025
Notes payable and accrued interest converted to common stock, Value	$ 146,717	402,061			548,778
Notes payable and accrued interest converted to common stock, Shares	146,717,525
Net loss			(559,367)		(559,367)
Stockholders' Equity, end of period, Value at Mar. 31, 2019	$ 361,577	$ 14,884,059	$ (13,022,181)	$ (1,000,000)	$ 1,223,455
Stockholders' Equity, end of period, Shares at Mar. 31, 2019	361,577,519

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (559,367)	$ (610,033)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	247	432
Amortization	173,967	173,967
Non cash interest expense	132,482	15,527
Stock-based compensation expense	1,025	0
Loss on extinguishment of debt	5,838	63,699
Change in fair value of derivative liability	53,163	118,101
Changes in operating assets and liabilities:
Accounts receivable	4,505	4,733
Inventory	85	0
Prepaid expenses and other current assets	0	16,856
Accounts payable and accrued expenses	90,061	(52,761)
Deferred revenue	(3,725)	(3,725)
NET CASH USED IN OPERATING ACTIVITIES	(101,719)	(273,204)
CASH FLOWS FROM INVESTING ACTIVITIES	0	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of convertible debt	114,000	309,000
Proceeds from sale of common stock	0	15,000
Proceeds from related party loans	6,386	0
Repayments of related party loans	(12,000)	0
NET CASH PROVIDED BY FINANCING ACTIVITIES	108,386	324,000
NET INCREASE IN CASH	6,667	50,796
CASH - BEGINNING OF PERIOD	369	9,449
CASH - END OF PERIOD	7,036	60,245
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for Interest	771	737
Non-cash investing and financing activities:
Debt discount related to derivative liability	206,000	43,249
Notes payable converted to common stock	270,957	102,000
Common stock issued in payment of accrued interest	$ 18,177	$ 12,346

Note 1 - Organization and Basis

Note 1 - Organization and Basis of Presentation	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Note 1 - Organization and Basis of Presentation	Note 1 - Organization and Basis of Presentation The consolidated financial statements presented are those of iGambit Inc., (the “Company”) and its wholly-owned subsidiary, HealthDatix, Inc. (“HealthDatix. The Company is a holding company which seeks out acquisitions of operating companies in technology markets. HealthDatix, Inc. is engaged in the business of streamlining the process of managing information in the document-intensive medical field for customers throughout the United States. Interim Financial Statements The following (a) condensed consolidated balance sheet as of December 31, 2018, which has been derived from audited financial statements, and (b) the unaudited condensed consolidated interim financial statements of the Company have been prepared in accordance with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2019 are not necessarily indicative of results that may be expected for the year ending December 31, 2019. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”) on April 16, 2019.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Note 2 - Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated. Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Fair Value Measurements The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions) The estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level 3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the three months ended March 31, 2019 and 2018. 2019 2018 Liabilities: Balance of derivative liabilities - beginning of period $ 288,242 $ 66,059 Issued 273,450 43,249 Converted (395,339 ) (227,409 ) Change in fair value recognized in operations 53,163 118,101 Balance of derivative liabilities - end of period $ 219,516 $ — Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities. Revenue Recognition Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. The Company has no outstanding contracts with any of is’ customers. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the three months ended March 31, 2019 and 2018. iGambit is a holding company and has no sources of revenue. HealthDatix’s revenues are derived primarily from its Software as a Service (SaaS) offerings that are rendered to healthcare providers. HealthDatix recognizes revenues when the products or services have been provided or delivered, the fees charged are fixed or determinable, HealthDatix and its customers understand the specific nature and terms of the agreed upon transactions, and collectability is reasonably assured. Advertising Costs The Company expenses advertising costs as incurred. There were no advertising costs charged to operations for the three months ended March 31, 2019 and 2018, respectively. Cash and Cash Equivalents For purposes of reporting cash flows, cash and cash equivalents include checking and money market accounts and any highly liquid debt instruments purchased with a maturity of three months or less. Accounts Receivable The Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly. A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances. The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment. Inventory Inventory consisting of finished products is stated at the lower of cost or net realizable value. Property and equipment and depreciation Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows: Office equipment and fixtures 5 - 7 years Computer hardware 5 years Computer software 3 years Development equipment 5 years Amortization Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows: Software 5 years Technology license 5 years Purchased in process R&D Indefinite Customer contracts 10 years Long-Lived Assets The Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows. Deferred Revenue Deposits from customers are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Company’s support and maintenance services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $5,467 and $9,192 as of March 31, 2019 and December 31, 2018, respectively. Stock-Based Compensation The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity, Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements . Recent Accounting Pronouncements We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

Note 3 - Going Concern

Note 3 - Going Concern	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Note 3 - Going Concern	Note 3 – Going Concern The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has an accumulated deficit of $13,022,181, and a working capital deficit of $1,178,484 at March 31, 2019. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company’s continuation as a going concern is dependent upon its ability to obtain necessary equity financing and ultimately from generating revenues from its newly acquired subsidiary to continue operations. The Company expects that working capital requirements will continue to be funded through a combination of its existing funds and further issuances of securities. Working capital requirements are expected to increase in line with the growth of the business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund operations over the next twelve months. The Company has no lines of credit or other bank financing arrangements. The Company has financed operations to date through the proceeds of a private placement of equity and debt instruments. In connection with the Company’s business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. The Company intends to finance these expenses with further issuances of securities, and debt issuances. Thereafter, the Company expects it will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to current stockholders. Further, such securities might have rights, preferences or privileges senior to common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, the Company may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict business operations. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 4 - Property and Equipment

Note 4 - Property and Equipment	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Note 4 - Property and Equipment	Note 4 – Property and Equipment Property and equipment are carried at cost and consist of the following at March 31, 2019 and December 31, 2018: 2019 2018 Office equipment and fixtures $ 10,964 $ 10,964 Less: Accumulated depreciation 9,093 8,846 $ 1,871 $ 2,118 Depreciation expense of $247 and $432 was charged to operations for the three months ended March 31, 2019 and 2018, respectively.

Note 5 - Intangible Assets

Note 5 - Intangible Assets	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Note 5 - Intangible Assets	Note 5 – Intangible Assets Intangible assets from the acquisitions of HealthDatix and ECSL consist of the following at March 31, 2019 and December 31, 2018: 2019 2018 Life Software $ 156,925 $ 156,925 5 years Customer contracts 644,846 644,846 10 years FDA 510K clearance 1,396,000 1,396,000 5 years Technology license 1,000,000 1,000,000 5 years In process research and development 604,000 604,000 Indefinite 3,801,771 3,801,771 Less: Accumulated amortization 1,403,723 1,229,756 $ 2,398,048 $ 2,572,015 Amortization expense of $173,967 was charged to operations for the three months ended March 31, 2019 and 2018, respectively.

Note 6 - Earnings (Loss) Per Co

Note 6 - Earnings (Loss) Per Common Share	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Note 6 - Earnings (Loss) Per Common Share	Note 6 - Earnings (Loss) Per Common Share The Company calculates net income (loss) per common share in accordance with ASC 260 “ Earnings Per Share Three Months Ended March 31, 2019 2018 Stock options 20,500,000 8,463,000 Stock warrants 1,875,000 1,150,000 Total shares excluded from calculation 22,375,000 9,613,000

Note 7 - Stock Based Compensati

Note 7 - Stock Based Compensation	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Note 7 - Stock Based Compensation	Note 7 – Stock Based Compensation Options In 2006, the Company adopted the 2006 Long-Term Incentive Plan (the "2006 Plan"). Awards granted under the 2006 Plan have a ten-year term and may be incentive stock options, non-qualified stock options or warrants. The awards are granted at an exercise price equal to the fair market value on the date of grant and generally vest over a three or four year period. The Plan expired on December 31, 2009, therefore as of March 31, 2019, there was no unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the 2006 plan. The 2006 Plan provided for the granting of options to purchase up to 10,000,000 shares of common stock. 8,146,900 options have been issued under the plan to date of which 7,157,038 have been exercised and 692,962 have expired to date. There were 296,900 options outstanding under the 2006 Plan on its expiration date of December 31, 2009. All options issued subsequent to this date were not issued pursuant to any plan. Stock option activity during the three months ended March 31, 2019 and 2018 follows: Options Outstanding Weighted Average Exercise Price Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Life (Years) Options outstanding at December 31, 2017 8,463,000 $ 0.07 $ 0.07 7.41 No option activity — — — Options outstanding at March 31, 2018 8,463,000 $ 0.07 0.07 7.16 Options outstanding at December 31, 2018 20,500,000 0.03 0.03 7.52 No option activity — — — Options outstanding at March 31, 2019 20,500,000 $ 0.03 $ 0.03 7.27 Options outstanding at March 31, 2019 consist of: Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date June 6, 2014 250,000 250,000 $ 0.05 June 6, 2019 March 24, 2015 200,000 200,000 $ 0.01 March 24, 2020 April 6, 2017 600,000 600,000 $ 0.03 April 6, 2027 June 6, 2017 700,000 700,000 $ 0.07 June 6, 2022 June 6, 2017 6,500,000 6,500,000 $ 0.07 June 6, 2027 November 1, 2018 12,250,000 12,250,000 $ 0.01 November 1, 2028 Total 20,500,000 20,500,000 Warrants In addition to our 2006 Long Term Incentive Plan, we have issued and outstanding compensatory warrants to two consultants entitling the holders to purchase a total of 275,000 shares of our common stock at an average exercise price of $0.94 per share. Warrants to purchase 25,000 shares of common stock vest upon 6 months after the Company engages in an IPO, have an exercise price of $3.00 per share, and expire 2 years after the Company engages in an IPO. Warrants to purchase 250,000 shares of common stock vest 100,000 shares on issuance (June 1, 2009), and 50,000 shares on each of the following three anniversaries of the date of issuance, have exercise prices ranging from $0.50 per share to $1.15 per share, and expire on June 1, 2019. The issuance of the compensatory warrants was not submitted to our shareholders for their approval. Warrant activity during the three months ended March 31, 2019 and 2018 follows: Warrants Outstanding Weighted Average Exercise Price Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Life (Years) Warrants outstanding at December 31, 2017 400,000 $ 0.62 $ 0.10 3.27 Warrant granted 750,000 0.05 — Warrants outstanding at March 31, 2018 1,150,000 $ 0.21 $ 0.10 3.64 Warrants outstanding at December 31, 2018 1,875,000 $ 0.12 $ 0.12 3.24 No warrant activity — — — Warrants outstanding at March 31, 2019 1,875,000 $ 0.12 $ 0.12 3.00 Warrants outstanding at March 31, 2019 consist of: Dater Issued Number Outstanding Number Exercisable Exercise Price Expiration Date June 1, 2009 100,000 100,000 $ 0.50 June 1, 2019 June 1, 2009 50,000 50,000 $ 0.65 June 1, 2019 June 1, 2009 50,000 50,000 $ 0.85 June 1, 2019 June 1, 2009 50,000 50,000 $ 1.15 June 1, 2019 January 1, 2017 50,000 50,000 $ 0.25 October 10, 2021 January 1, 2017 50,000 50,000 $ 0.50 November 7, 2021 January 5, 2017 25,000 25,000 $ 0.50 January 5, 2022 February 5, 2018 750,000 750,000 $ 0.05 February 5, 2023 April 27, 2018 750,000 750,000 $ 0.05 April 27, 2023 Total 1,875,000 1,875,000

Note 8 - Convertible Debt

Note 8 - Convertible Debt	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Note 8 - Convertible Debt	Note 8 – Convertible Debt Convertible Notes Payable On January 10, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $240,000, convertible into shares of the Company’s common stock, and includes a back-ended note with principal of $120,000 that was funded on July 10, 2018. The back-ended Note, including accrued interest is due July 10, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 15 trading day period ending on the latest complete trading day prior to the conversion date. During the three months ended March 31, 2019, the noteholder converted $66,000 of the principal balance and accrued interest of $4,995 to 44,490,002 shares of common stock. The balance of the note was $100,000 on March 31, 2019. On March 6, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $126,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due March 6, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the lowest trading price during the 20 trading day period ending on the latest complete trading day prior to and including the conversion date. During the three months ended March 31, 2019, the noteholder converted the remaining principal balance of $60,000 and accrued interest of $4,342 to 35,446,300 shares of common stock. On May 3, 2018, the Company entered into a Convertible Promissory Note pursuant to which the Company borrowed in the aggregate principal amount of $83,500. The convertible note is due 12 months after issuance and bears interest at a rate of 8%. The Note is convertible into shares of common stock of the Company 180 days following the date of funding and thereafter. The conversion price shall be subject to a discount of 35% applied to the average of the three lowest closing bid prices of the Common Stock during the prior twenty (20) trading day period. The Investor will be limited to convert no more than 4.99% of the issued and outstanding Common Stock at the time of conversion at any one time. At any time during the period beginning on the date of the Note and ending on the date which is 180 days thereafter, the Company may repay the Note by paying an amount equal to the then outstanding amount multiplied by 130%. During the three months ended March 31, 2019, the noteholder converted the remaining principal balance of $53,957 and accrued interest of $4,600 to 25,674,344 shares of common stock. On June 25, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $53,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due April 15, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. During the three months ended March 31, 2019, the noteholder converted the remaining principal balance of $38,000 and accrued interest of $2,120 to 14,859,260 shares of common stock. On August 13, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $53,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due May 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. During the three months ended March 31, 2019, the noteholder converted the principal balance of the note and accrued interest of $2,120 to 26,247,619 shares of common stock. On September 17, 2018, the Company issued an 8% convertible note in the aggregate principal amount of $33,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due June 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. On January 3, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due October 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. On February 15, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due November 30, 2019 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. On March 29, 2019, the Company issued an 8% convertible note in the aggregate principal amount of $38,000, convertible into shares of the Company’s common stock. The Note, including accrued interest is due February 15, 2020 and is convertible any time after 180 days at the option of the holder into shares of the Company’s common stock at 65% of the average stock price of the lowest 3 closing bid prices during the 10 trading day period ending on the latest complete trading day prior to the conversion date. The Company recorded a debt discount related to identified embedded derivatives relating to conversion features and a reset provisions (see Note 9) based fair values as of the inception date of the Notes. The calculated debt discount equaled the face of the 8% note dated January 10, 2018 and is being amortized and revalued over the term of the note. The calculated debt discount equaled the face of the 8% note dated March 6, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated May 3, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated June 25, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated August 13, 2018 and was amortized through the date the convertible debt was fully extinguished. The calculated debt discount equaled the face of the 8% note dated September 17, 2018 and is being amortized and revalued over the term of the note. Interest expense on the convertible notes of $130,362 and $14,878 was recorded for the three months ended March 31, 2019 and 2018, respectively. The Company issued convertible debentures in the amount of $75,000 to three individuals. The debentures are convertible into 75,000 shares of common stock for up to 5 years, at the holders’ option, at an exercise price of $.50 and $.25, respectively. The debentures mature on the earlier of the closing of a subsequent financing event by the Company resulting in gross proceeds of at least $10,000,000 or three years from the date of issuance. The debentures bear interest at a rate of 10%. A beneficial conversion feature was not recorded as the fair market value of the Company’s common stock was less than the exercise prices at the dates of issuance and through the end of the year. Interest expense on the convertible debentures of $2,120 and $1,829 was recorded for the three months ended March 31, 2019 and 2018, respectively. Convertible notes payable at March 31, 2019 and December 31, 2018 are summarized as follows: 2019 2018 Total face value of notes $ 322,000 $ 478,957 Less: Discount 107,632 101,346 Balance $ 214,368 $ 377,611

Note 9 - Derivative Liability

Note 9 - Derivative Liability	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Note 9 - Derivative Liability	Note 9 – Derivative Liability The Company has determined that the conversion feature embedded in the convertible notes described in Note 8 contain a potential variable conversion amount which constitutes a derivative which has been bifurcated from the note and recorded as a derivative liability at fair value, with a corresponding discount recorded to the associated debt. The excess of the derivative value over the face amount of the note is recorded immediately to interest expense at inception. The Company used the Binomial Option Pricing model to value the conversion features. The Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using a Black-Scholes option-pricing model with the following assumption inputs: March 31, December 31, 2019 2018 Annual dividend yield — — Expected life (years) 0.78 - 1.0 0.77 - 1.0 Risk-free interest rate 2.44% - 2.52% 2.07% - 2.57% Expected volatility 274% - 280% 257% - 293% Based upon ASC 840-15-25 (EITF Issue 00-19, paragraph 11) the Company has adopted a sequencing approach regarding the application of ASC 815-40 to its outstanding convertible notes. Pursuant to the sequencing approach, the Company evaluates its contracts based upon earliest issuance date.

Note 10 - Note Payable

Note 10 - Note Payable	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Note 10 - Note Payable	Note 10 – Notes Payable Notes payable at March 31, 2019 and December 31, 2018 consists of loans to HealthDatix from 3 individuals totaling $52,500. The loans do not bear interest and there are no specific terms for repayment.

Note 11 - Stock Transactions

Note 11 - Stock Transactions	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Note 11 - Stock Transactions	Note 11 – Stock Transactions Designation of Preferred Stock On August 2, 2018, the Company filed a Certificate of Designation with the Delaware Division of Corporations whereby the Company designated a Series A Preferred Stock and issued 1,000 shares to the Company’s CEO. The holders of Series A Preferred Stock will have voting rights, when combined with their existing holdings of the Company’s common stock, that entitle them to have an aggregate of 51% of the votes eligible to be cast by all stockholders with respect to all matters brought before a vote of the stockholders of the Company. Common Stock Issued On August 8, 2018, the Board unanimously approved an amendment to the Company’s Articles of Incorporation to increase the number of shares of Common Stock which the Company is authorized to issue from Four hundred million (400,000,000) to Eight Hundred Million (800,000,000) shares of Common Stock, $0.001 par value per share. In connection with the convertible notes payable (see Note 8 above) the noteholders converted $270,957 of principal balance and $18,177 of accrued interest to 146,717,525 shares of common stock during the three months ended March 31, 2019. The stock issued was determined based on the terms of the convertible notes.

Note 12 - Income Taxes

Note 12 - Income Taxes	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Note 12 - Income Taxes	Note 12 - Income Taxes A full valuation allowance was recorded against the Company’s net deferred tax assets. A valuation allowance must be established if it is more likely than not that the deferred tax assets will not be realized. This assessment is based upon consideration of available positive and negative evidence, which includes, among other things, the Company’s most recent results of operations and expected future profitability. Based on the Company’s cumulative losses in recent years, a full valuation allowance against the Company’s deferred tax assets has been established as Management believes that the Company will not realize the benefit of those deferred tax assets.

Note 13 - Concentrations and Cr

Note 13 - Concentrations and Credit Risk	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Note 13 - Concentrations and Credit Risk	Note 13 – Concentrations and Credit Risk Sales and Accounts Receivable HealthDatix had sales to three customers which accounted for approximately 24%, 17%, and 17%, respectively of HealthDatix’s total sales for the three months ended March 31, 2019. One customer accounted for approximately 96% of accounts receivable at March 31, 2019. HealthDatix had sales to four customers which accounted for approximately 30%, 21%, 21%, and 19%, respectively of HealthDatix’s total sales for the three months ended March 31, 2018. One customer accounted for 100% of accounts receivable at March 31, 2018. Cash Cash is maintained at a major financial institution. Accounts held at U.S. financial institutions are insured by the FDIC up to $250,000. Cash balances could exceed insured amounts at any given time, however, the Company has not experienced any such losses. The Company did not have any interest-bearing accounts at March 31, 2019 and December 31, 2018, respectively.

Note 14 - Related Party Transac

Note 14 - Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Note 14 - Related Party Transactions	Note 14 - Related Party Transactions Amounts Due to Related Parties Amounts due to related parties with balances of $139,753 and $145,367 at March 31, 2019 and December 31, 2018, respectively, do not bear interest and are payable on demand. The Company’s former subsidiary, Arcmail owed amounts on a credit card that is guaranteed by the husband of the Company’s Executive Vice President, who was held personally responsible by the credit card company for the unpaid balance.

Note 15 - Commitments and Conti

Note 15 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Note 15 - Commitments and Contingencies	Note 15 – Commitments and Contingencies Lease Commitment The Company is obligated under an operating lease for its premises in Smithtown, New York that expires on May 31, 2019. The lease was not renewed and the officers of the Company will provide office space to the Company at no charge. Total future minimum annual lease payments under the lease for the years ending December 31 are as follows: 2019 $ 3,380 Rent expense of $7,728 and $7,048 was charged to operations for the three months ended March 31, 2019 and 2018, respectively. Employment Arrangements With Executive Officers Effective April 1, 2017, in connection with the acquisition of HealthDatix Inc., the Company entered into employment agreements with Jerry Robinson, MaryJo Robinson, and Kathleen Shepherd each under a three-year term at a base salary of $75,000 per year, bonuses based upon objectives set by the Company, and participation in all benefit programs generally made available to HealthDatix employees. The employment agreements restrict the executive officers from engaging in certain competitive activities for the greater of 60 months from the date of the agreements or two years following the termination of their respective employment.

Note 16 - Subsequent Events

Note 16 - Subsequent Events	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Note 16 - Subsequent Events	Note 16 – Subsequent Events Common Stock Issued Subsequent to the end of the period through the date of the report, a noteholder converted $55,232 of principal and $1,691 of accrued interest to 35,966,371 shares of the Company’s common stock.

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Policy Text Block [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated.
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
Fair Value Measurements	Fair Value Measurements The Company adopted the provisions of ASC Topic 820, Fair Value Measurements and Disclosures, The estimated fair value of certain financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued expenses are carried at historical cost basis, which approximates their fair values because of the short-term nature of these instruments. The carrying amounts of our short- and long-term credit obligations approximate fair value because the effective yields on these obligations, which include contractual interest rates taken together with other features such as concurrent issuances of warrants and/or embedded conversion options, are comparable to rates of returns for instruments of similar credit risk. ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 – quoted prices in active markets for identical assets or liabilities Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable Level 3 – inputs that are unobservable (for example cash flow modeling inputs based on assumptions) The estimated fair value of the derivative liability was calculated using the Black-Scholes option pricing model. The Company uses Level 3 inputs to value its derivative liabilities. The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the three months ended March 31, 2019 and 2018. 2019 2018 Liabilities: Balance of derivative liabilities - beginning of period $ 288,242 $ 66,059 Issued 273,450 43,249 Converted (395,339 ) (227,409 ) Change in fair value recognized in operations 53,163 118,101 Balance of derivative liabilities - end of period $ 219,516 $ —
Convertible Instruments	Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC 815, Derivatives and Hedging Activities. Applicable GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under other GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when it has been determined that the embedded conversion options should not be bifurcated from their host instruments) as follows: The Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company accounts for the conversion of convertible debt when a conversion option has been bifurcated using the general extinguishment standards. The debt and equity linked derivatives are removed at their carrying amounts and the shares issued are measured at their then-current fair value, with any difference recorded as a gain or loss on extinguishment of the two separate accounting liabilities.
Revenue Recognition	Revenue Recognition Effective January 1, 2018, the Company adopted ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the commercial sales of products by: (1) identify the contract (if any) with a customer; (2) identify the performance obligations in the contract (if any); (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract (if any); and (5) recognize revenue when each performance obligation is satisfied. For the comparative periods, revenue has not been adjusted and continues to be reported under ASC 605 — Revenue Recognition. Under ASC 605, revenue is recognized when the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) the performance of service has been rendered to a customer or delivery has occurred; (3) the amount of fee to be paid by a customer is fixed and determinable; and (4) the collectability of the fee is reasonably assured. The Company has no outstanding contracts with any of is’ customers. There was no impact on the Company’s financial statements as a result of adopting Topic 606 for the three months ended March 31, 2019 and 2018. iGambit is a holding company and has no sources of revenue. HealthDatix’s revenues are derived primarily from its Software as a Service (SaaS) offerings that are rendered to healthcare providers. HealthDatix recognizes revenues when the products or services have been provided or delivered, the fees charged are fixed or determinable, HealthDatix and its customers understand the specific nature and terms of the agreed upon transactions, and collectability is reasonably assured.
Advertising Costs	Advertising Costs The Company expenses advertising costs as incurred. There were no advertising costs charged to operations for the three months ended March 31, 2019 and 2018, respectively.
Cash and Cash Equivalents	Cash and Cash Equivalents For purposes of reporting cash flows, cash and cash equivalents include checking and money market accounts and any highly liquid debt instruments purchased with a maturity of three months or less.
Accounts Receivable	Accounts Receivable The Company analyzes the collectability of accounts receivable from continuing operations each accounting period and adjusts its allowance for doubtful accounts accordingly. A considerable amount of judgment is required in assessing the realization of accounts receivables, including the creditworthiness of each customer, current and historical collection history and the related aging of past due balances. The Company evaluates specific accounts when it becomes aware of information indicating that a customer may not be able to meet its financial obligations due to deterioration of its financial condition, lower credit ratings, bankruptcy or other factors affecting the ability to render payment.
Inventory	Inventory Inventory consisting of finished products is stated at the lower of cost or net realizable value.
Property and equipment and depreciation	Property and equipment and depreciation Property and equipment are stated at cost. Maintenance and repairs are charged to expense when incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts and any gain or loss is credited or charged to income. Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows: Office equipment and fixtures 5 - 7 years Computer hardware 5 years Computer software 3 years Development equipment 5 years
Amortization	Amortization Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows: Software 5 years Technology license 5 years Purchased in process R&D Indefinite Customer contracts 10 years
Long-Lived Assets	Long-Lived Assets The Company assesses the valuation of components of its property and equipment and other long-lived assets whenever events or circumstances dictate that the carrying value might not be recoverable. The Company bases its evaluation on indicators such as the nature of the assets, the future economic benefit of the assets, any historical or future profitability measurements and other external market conditions or factors that may be present. If such factors indicate that the carrying amount of an asset or asset group may not be recoverable, the Company determines whether an impairment has occurred by analyzing an estimate of undiscounted future cash flows at the lowest level for which identifiable cash flows exist. If the estimate of undiscounted cash flows during the estimated useful life of the asset is less than the carrying value of the asset, the Company recognizes a loss for the difference between the carrying value of the asset and its estimated fair value, generally measured by the present value of the estimated cash flows.
Deferred Revenue	Deferred Revenue Deposits from customers are not recognized as revenues, but as liabilities, until the following conditions are met: revenues are realized when cash or claims to cash (receivable) are received in exchange for goods or services or when assets received in such exchange are readily convertible to cash or claim to cash or when such goods/services are transferred. When such income item is earned, the related revenue item is recognized, and the deferred revenue is reduced. To the extent revenues are generated from the Company’s support and maintenance services, the Company recognizes such revenues when services are completed and billed. The Company has received deposits from its various customers that have been recorded as deferred revenue and presented as current liabilities in the amount of $5,467 and $9,192 as of March 31, 2019 and December 31, 2018, respectively.
Stock-Based Compensation	Stock-Based Compensation The Company accounts for its stock-based awards granted under its employee compensation plan in accordance with ASC Topic No. 718-20, Awards Classified as Equity,
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method in accordance with ASC Topic No. 740, Income Taxes The Company applies the provisions of ASC Topic No. 740 for the financial statement recognition, measurement and disclosure of uncertain tax positions recognized in the Company’s financial statements .
Recent Accounting Pronouncements	Recent Accounting Pronouncements We have reviewed other recent accounting pronouncements and concluded they are either not applicable to the business, or no material effect is expected on the condensed consolidated financial statements as a result of future adoption.

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Fair value assets and liabilities measured on recurring basis	The following table provides a reconciliation of the beginning and ending balances for the major classes of assets and liabilities measured at fair value using significant unobservable inputs (Level 3) and reflects gains and losses for the three months ended March 31, 2019 and 2018. 2019 2018 Liabilities: Balance of derivative liabilities - beginning of period $ 288,242 $ 66,059 Issued 273,450 43,249 Converted (395,339 ) (227,409 ) Change in fair value recognized in operations 53,163 118,101 Balance of derivative liabilities - end of period $ 219,516 $ —
Schedule of estimated lives of respective assets	Depreciation for both financial reporting and income tax purposes is computed using combinations of the straight line and accelerated methods over the estimated lives of the respective assets as follows: Office equipment and fixtures 5 - 7 years Computer hardware 5 years Computer software 3 years Development equipment 5 years
Schedule of estimated lives of the respective assets	Intangible assets are amortized using the straight line method over the estimated lives of the respective assets as follows: Software 5 years Technology license 5 years Purchased in process R&D Indefinite Customer contracts 10 years

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Schedule of property, plant and equipment	Property and equipment are carried at cost and consist of the following at March 31, 2019 and December 31, 2018: 2019 2018 Office equipment and fixtures $ 10,964 $ 10,964 Less: Accumulated depreciation 9,093 8,846 $ 1,871 $ 2,118

Note 5 - Intangible Assets (Tab

Note 5 - Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Schedule of intangible assets	Intangible assets from the acquisitions of HealthDatix and ECSL consist of the following at March 31, 2019 and December 31, 2018: 2019 2018 Life Software $ 156,925 $ 156,925 5 years Customer contracts 644,846 644,846 10 years FDA 510K clearance 1,396,000 1,396,000 5 years Technology license 1,000,000 1,000,000 5 years In process research and development 604,000 604,000 Indefinite 3,801,771 3,801,771 Less: Accumulated amortization 1,403,723 1,229,756 $ 2,398,048 $ 2,572,015

Note 6 - Earnings (Loss) Per _2

Note 6 - Earnings (Loss) Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Computation of diluted net income (loss) per share	The Company’s potentially dilutive shares, which include outstanding common stock options and common stock warrants, have not been included in the computation of diluted net loss per share for the three months ended March 31, 2019 and 2018 as the result would be anti-dilutive. Three Months Ended March 31, 2019 2018 Stock options 20,500,000 8,463,000 Stock warrants 1,875,000 1,150,000 Total shares excluded from calculation 22,375,000 9,613,000

Note 7 - Stock Based Compensa_2

Note 7 - Stock Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Schedule of stock option activities	Stock option activity during the three months ended March 31, 2019 and 2018 follows: Options Outstanding Weighted Average Exercise Price Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Life (Years) Options outstanding at December 31, 2017 8,463,000 $ 0.07 $ 0.07 7.41 No option activity — — — Options outstanding at March 31, 2018 8,463,000 $ 0.07 0.07 7.16 Options outstanding at December 31, 2018 20,500,000 0.03 0.03 7.52 No option activity — — — Options outstanding at March 31, 2019 20,500,000 $ 0.03 $ 0.03 7.27
Schedule of stock options outstanding	Options outstanding at March 31, 2019 consist of: Date Issued Number Outstanding Number Exercisable Exercise Price Expiration Date June 6, 2014 250,000 250,000 $ 0.05 June 6, 2019 March 24, 2015 200,000 200,000 $ 0.01 March 24, 2020 April 6, 2017 600,000 600,000 $ 0.03 April 6, 2027 June 6, 2017 700,000 700,000 $ 0.07 June 6, 2022 June 6, 2017 6,500,000 6,500,000 $ 0.07 June 6, 2027 November 1, 2018 12,250,000 12,250,000 $ 0.01 November 1, 2028 Total 20,500,000 20,500,000
Schedule of Warrants, Activity	Warrant activity during the three months ended March 31, 2019 and 2018 follows: Warrants Outstanding Weighted Average Exercise Price Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Life (Years) Warrants outstanding at December 31, 2017 400,000 $ 0.62 $ 0.10 3.27 Warrant granted 750,000 0.05 — Warrants outstanding at March 31, 2018 1,150,000 $ 0.21 $ 0.10 3.64 Warrants outstanding at December 31, 2018 1,875,000 $ 0.12 $ 0.12 3.24 No warrant activity — — — Warrants outstanding at March 31, 2019 1,875,000 $ 0.12 $ 0.12 3.00
Schedule of Outstanding Warrants	Warrants outstanding at March 31, 2019 consist of: Dater Issued Number Outstanding Number Exercisable Exercise Price Expiration Date June 1, 2009 100,000 100,000 $ 0.50 June 1, 2019 June 1, 2009 50,000 50,000 $ 0.65 June 1, 2019 June 1, 2009 50,000 50,000 $ 0.85 June 1, 2019 June 1, 2009 50,000 50,000 $ 1.15 June 1, 2019 January 1, 2017 50,000 50,000 $ 0.25 October 10, 2021 January 1, 2017 50,000 50,000 $ 0.50 November 7, 2021 January 5, 2017 25,000 25,000 $ 0.50 January 5, 2022 February 5, 2018 750,000 750,000 $ 0.05 February 5, 2023 April 27, 2018 750,000 750,000 $ 0.05 April 27, 2023 Total 1,875,000 1,875,000

Note 8 - Convertible Debt (Tabl

Note 8 - Convertible Debt (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Schedule of convertible notes payable	Convertible notes payable at March 31, 2019 and December 31, 2018 are summarized as follows: 2019 2018 Total face value of notes $ 322,000 $ 478,957 Less: Discount 107,632 101,346 Balance $ 214,368 $ 377,611

Note 9 - Derivative Liability (

Note 9 - Derivative Liability (Tables)	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Schedule of Valuation Assumptions	The Company used Level 3 inputs for its valuation methodology for the conversion option liability in determining the fair value using a Black-Scholes option-pricing model with the following assumption inputs: March 31, December 31, 2019 2018 Annual dividend yield — — Expected life (years) 0.78 - 1.0 0.77 - 1.0 Risk-free interest rate 2.44% - 2.52% 2.07% - 2.57% Expected volatility 274% - 280% 257% - 293%

Note 15 - Commitments and Con_2

Note 15 - Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2019
Disclosure Text Block [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases	Total future minimum annual lease payments under the lease for the years ending December 31 are as follows: 2019 $ 3,380

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Liabilities:
Balance of derivative liabilities - beginning of year	$ 288,242	$ 66,059
Issued	273,450	43,249
Converted	(395,339)	(227,409)
Change in fair value of derivative liabilities	53,163	118,101
Balance of derivative liabilities - end of period	$ 219,516	$ 0

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies (Details 1)	3 Months Ended
	Mar. 31, 2019
Computer hardware
Office equipment useful life	5 years
Computer software
Office equipment useful life	3 years
Development equipment
Office equipment useful life	5 years
Maximum | Office equipment and fixtures
Office equipment useful life	7 years
Minimum | Office equipment and fixtures
Office equipment useful life	5 years

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies (Details 2)	3 Months Ended
	Mar. 31, 2019
Technology license
Intangible assets useful life	5 years
Customer contracts
Intangible assets useful life	10 years
FDA 510K clearance
Intangible assets useful life	5 years
In process research and development
Intangible assets useful life	Indefinite
Software
Intangible assets useful life	5 years

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies (Details Narratives) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Disclosure Text Block [Abstract]
Advertising costs	$ 0	$ 0
Deferred revenue	$ 5,467		$ 9,192

Note 3 - Going Concern (Details

Note 3 - Going Concern (Details Narrative) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Disclosure Text Block [Abstract]
Accumulated deficit	$ (13,022,181)	$ (12,462,814)
Working capital deficit	$ (1,178,484)

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Disclosure Text Block [Abstract]
Office equipment and fixtures	$ 10,964	$ 10,964
Less: accumulated depreciation	9,093	8,846
Property, Plant and Equipment, Net	$ 1,871	$ 2,118

Note 4 - Property and Equipme_4

Note 4 - Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disclosure Text Block [Abstract]
Depreciation expense	$ 247	$ 432

Note 5 - Intangible Assets (Det

Note 5 - Intangible Assets (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Intangible Assets, Gross	$ 3,801,771	$ 3,801,771
Less: Accumulated amortization	1,403,723	1,229,756
Intangible Assets, Net	2,398,048	2,572,015
Technology license
Intangible Assets, Gross	$ 1,000,000	1,000,000
Intangible assets useful life	5 years
Customer contracts
Intangible Assets, Gross	$ 644,846	644,846
Intangible assets useful life	10 years
FDA 510K clearance
Intangible Assets, Gross	$ 1,396,000	1,396,000
Intangible assets useful life	5 years
In process research and development
Intangible Assets, Gross	$ 604,000	604,000
Intangible assets useful life	Indefinite
Software
Intangible Assets, Gross	$ 156,925	$ 156,925
Intangible assets useful life	5 years

Note 5 - Intangible Assets (D_2

Note 5 - Intangible Assets (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disclosure Text Block [Abstract]
Amortization expense	$ 173,967	$ 173,967

Note 6 - Earnings (Loss) Per _3

Note 6 - Earnings (Loss) Per Common Share (Details) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Total shares excluded from calculation	22,375,000	9,613,000
Warrant
Total shares excluded from calculation	1,875,000	1,150,000
Options
Total shares excluded from calculation	20,500,000	8,463,000

Note 7 - Stock Based Compensa_3

Note 7 - Stock Based Compensation (Details) - $ / shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disclosure Text Block [Abstract]
Options, Outstanding, Beginning Balance	20,500,000	8,463,000
Options, Outstanding, Beginning Balance, Weighted Average Exercise Price	$ 0.03	$ 0.07
Options, Outstanding, Beginning Balance, Weighted Average Grant-Date Fair Value	$ 0.03	$ 0.07
Options, Outstanding, Beginning Weighted Average Remaining Contractual Term	7 years 6 months 7 days	7 years 4 months 28 days
Options, Outstanding, Ending Balance	20,500,000	8,463,000
Options, Outstanding, Ending Balance, Weighted Average Exercise Price	$ 0.03	$ 0.07
Options, Outstanding, Ending Balance, Weighted Average Grant-Date Fair Value	$ 0.03	$ 0.07
Options, Outstanding, Ending Weighted Average Remaining Contractual Term	7 years 3 months 8 days	7 years 1 month 27 days

Note 7 - Stock Based Compensa_4

Note 7 - Stock Based Compensation (Details 1) - $ / shares	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Number of Outstanding	20,500,000	20,500,000	8,463,000	8,463,000
Number Exercisable	20,500,000
Exercise price	$ 0.03	$ 0.03	$ 0.07	$ 0.07
Options Two
Issued Date	Mar. 24, 2015
Number of Outstanding	200,000
Number Exercisable	200,000
Exercise price	$ 0.01
Options outstanding Expiration Date	Mar. 24, 2020
Options Three
Issued Date	Apr. 6, 2017
Number of Outstanding	600,000
Number Exercisable	600,000
Exercise price	$ 0.03
Options outstanding Expiration Date	Apr. 6, 2027
Options Four
Issued Date	Jun. 6, 2017
Number of Outstanding	700,000
Number Exercisable	700,000
Exercise price	$ 0.07
Options outstanding Expiration Date	Jun. 6, 2022
Options Five
Issued Date	Jun. 6, 2017
Number of Outstanding	6,500,000
Number Exercisable	6,500,000
Exercise price	$ 0.07
Options outstanding Expiration Date	Jun. 6, 2027
Options Six
Issued Date	Nov. 1, 2018
Number of Outstanding	12,250,000
Number Exercisable	12,250,000
Exercise price	$ 0.01
Options outstanding Expiration Date	Nov. 1, 2028
Options One
Issued Date	Jun. 6, 2014
Number of Outstanding	250,000
Number Exercisable	250,000
Exercise price	$ 0.05
Options outstanding Expiration Date	Jun. 6, 2019

Note 7 - Stock Based Compensa_5

Note 7 - Stock Based Compensation (Details 2) - $ / shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Text Block [Abstract]
Warrants, Outstanding, Beginning Balance	1,875,000	400,000
Warrants, Outstanding, Beginning Balance, Weighted Average Exercise Price	$ 0.12	$ 0.62
Warrants, Outstanding, Beginning Balance, Weighted Average Grant-Date Fair Value	$ 0.12	$ 0.1
Warrants, Outstanding, Beginning Balance, Weighted Average Remaining Contractual Life	3 years 2 months 27 days	3 years 3 months 8 days
Warrants, Outstanding, Ending Balance	1,875,000	1,150,000
Warrants, Outstanding, Ending Balance, Weighted Average Exercise Price	$ 0.12	$ 0.21
Warrants, Outstanding, Ending Balance, Weighted Average Grant-Date Fair Value	$ 0.12	$ 0.1
Warrants, Outstanding, Beginning Balance, Weighted Average Remaining Contractual Life	3 years	3 years 7 months 21 days

Note 7 - Stock Based Compensa_6

Note 7 - Stock Based Compensation (Details 3)	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Number of Outstanding	1,875,000
Number Exercisable	1,875,000
Warrants One
Issued Date	Jun. 1, 2009
Number of Outstanding	100,000
Number Exercisable	100,000
Exercise price | $ / shares	$ 0.5
Expiration Date	Jun. 1, 2019
Warrants Two
Issued Date	Jun. 1, 2009
Number of Outstanding	50,000
Number Exercisable	50,000
Exercise price | $ / shares	$ 0.65
Expiration Date	Jun. 1, 2019
Warrants Three
Issued Date	Jun. 1, 2009
Number of Outstanding	50,000
Number Exercisable	50,000
Exercise price | $ / shares	$ 0.85
Expiration Date	Jun. 1, 2019
Warrants Four
Issued Date	Jun. 1, 2009
Number of Outstanding	50,000
Number Exercisable	50,000
Exercise price | $ / shares	$ 1.15
Expiration Date	Jun. 1, 2019
Warrants Five
Issued Date	Jan. 1, 2017
Number of Outstanding	50,000
Number Exercisable	50,000
Exercise price | $ / shares	$ 0.25
Expiration Date	Oct. 10, 2021
Warrants Six
Issued Date	Jan. 1, 2017
Number of Outstanding	50,000
Number Exercisable	50,000
Exercise price | $ / shares	$ 0.5
Expiration Date	Nov. 7, 2021
Warrants Seven
Issued Date	Jan. 5, 2017
Number of Outstanding	25,000
Number Exercisable	25,000
Exercise price | $ / shares	$ 0.5
Expiration Date	Jan. 5, 2022
Warrants Eight
Issued Date	Feb. 5, 2018
Number of Outstanding	750,000
Number Exercisable	750,000
Exercise price | $ / shares	$ 0.05
Expiration Date	Feb. 5, 2023
Warrants Nine
Issued Date	Apr. 27, 2018
Number of Outstanding	750,000
Number Exercisable	750,000
Exercise price | $ / shares	$ 0.05
Expiration Date	Apr. 27, 2023

Note 8 - Convertible Debt (Deta

Note 8 - Convertible Debt (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Disclosure Text Block [Abstract]
Total face value of notes	$ 322,000	$ 478,957
Less: Discount	107,632	101,346
Balance	$ 214,368	$ 377,611

Note 8 - Convertible Debt (De_2

Note 8 - Convertible Debt (Details Narrative) - USD ($)

Jan. 03, 2019

Aug. 13, 2018

May 03, 2018

Mar. 06, 2018

Jan. 10, 2018

Mar. 29, 2019

Feb. 15, 2019

Sep. 17, 2018

Jun. 25, 2018

Mar. 30, 2017

Mar. 31, 2019

Mar. 31, 2018

Interest expense on the convertible notes

$ 130,362

$ 14,878

Interest expense on the convertible debentures

$ 2,120

$ 1,829

Maturity date

Mar. 31, 2017

ConvertibleNoteTwelveMember

Debt Conversion, Converted Instrument, Amount

$ 38,000

Interest rate

8.00%

Maturity date

Oct. 30, 2019

ConvertibleNoteEightMember

Debt Conversion, Converted Instrument, Shares Issued

25,674,344

ConvertibleNoteSevenMember

Debt Conversion, Converted Instrument, Shares Issued

35,446,300

ConvertibleNoteFiveMember

Debt Conversion, Converted Instrument, Shares Issued

44,490,002

Convertible note

$ 100,000

ConvertibleNoteTenMember

Debt Conversion, Converted Instrument, Shares Issued

26,247,619

ConvertibleNoteThirteenMember

Debt Conversion, Converted Instrument, Amount

$ 38,000

Interest rate

8.00%

Maturity date

Nov. 30, 2019

ConvertibleNoteNineMember

Debt Conversion, Converted Instrument, Shares Issued

14,859,260

ConvertibleNoteFourteenMember

Debt Conversion, Converted Instrument, Amount

$ 38,000

Interest rate

8.00%

Maturity date

Feb. 15, 2020

Noteholder

Debt Conversion, Converted Instrument, Shares Issued

146,717,525

Principal | ConvertibleNoteEightMember

Debt Conversion, Converted Instrument, Amount

$ 83,500

$ 53,957

Interest rate

8.00%

Maturity date

May 3, 2019

Principal | ConvertibleNoteSevenMember

Debt Conversion, Converted Instrument, Amount

$ 126,000

60,000

Interest rate

8.00%

Maturity date

Mar. 6, 2019

Principal | ConvertibleNoteFiveMember

Debt Conversion, Converted Instrument, Amount

$ 240,000

66,000

Interest rate

8.00%

Maturity date

Jul. 10, 2018

Principal | ConvertibleNoteTenMember

Debt Conversion, Converted Instrument, Amount

$ 53,000

53,000

Interest rate

8.00%

Maturity date

May 30, 2019

Principal | ConvertibleNoteElevenMember

Debt Conversion, Converted Instrument, Amount

$ 33,000

Interest rate

8.00%

Maturity date

Jun. 30, 2019

Principal | ConvertibleNoteNineMember

Debt Conversion, Converted Instrument, Amount

$ 53,000

38,000

Interest rate

8.00%

Maturity date

Apr. 15, 2019

Principal | 8% Convertible Note

Debt Conversion, Converted Instrument, Amount

$ 75,000

Interest rate

8.00%

Maturity date

Jun. 25, 2018

Principal | Noteholder

Debt Conversion, Converted Instrument, Amount

270,957

Accrued interest | ConvertibleNoteEightMember

Debt Conversion, Converted Instrument, Amount

4,600

Accrued interest | ConvertibleNoteSevenMember

Debt Conversion, Converted Instrument, Amount

4,342

Accrued interest | ConvertibleNoteFiveMember

Debt Conversion, Converted Instrument, Amount

4,995

Accrued interest | ConvertibleNoteTenMember

Debt Conversion, Converted Instrument, Amount

2,120

Accrued interest | ConvertibleNoteNineMember

Debt Conversion, Converted Instrument, Amount

2,120

Accrued interest | Noteholder

Debt Conversion, Converted Instrument, Amount

$ 18,177

Note 9 - Derivative Liability_2

Note 9 - Derivative Liability (Details)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Annual dividend yield	0.00%	0.00%
Maximum
Expected life (years)	1 year	1 year
Risk-free interest rate	2.52%	2.57%
Expected volatility	280.00%	293.00%
Minimum
Expected life (years)	9 months 11 days	9 months 7 days
Risk-free interest rate	2.44%	2.07%
Expected volatility	274.00%	257.00%

Note 10 - Note Payable (Details

Note 10 - Note Payable (Details Narratives) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Disclosure Text Block [Abstract]
Notes payable from discontinued operations	$ 52,500	$ 52,500

Note 11 - Stock Transactions (D

Note 11 - Stock Transactions (Details Narrative) - USD ($)

Jan. 03, 2019

Aug. 13, 2018

May 03, 2018

Mar. 06, 2018

Jan. 10, 2018

Mar. 29, 2019

Feb. 15, 2019

Sep. 17, 2018

Jun. 25, 2018

Mar. 30, 2017

Mar. 31, 2019

Dec. 31, 2018

Common stock, shares authorized

800,000,000

800,000,000

ConvertibleNoteTwelveMember

Debt Conversion, Converted Instrument, Amount

$ 38,000

ConvertibleNoteEightMember

Debt Conversion, Converted Instrument, Shares Issued

25,674,344

ConvertibleNoteSevenMember

Debt Conversion, Converted Instrument, Shares Issued

35,446,300

ConvertibleNoteFiveMember

Debt Conversion, Converted Instrument, Shares Issued

44,490,002

ConvertibleNoteTenMember

Debt Conversion, Converted Instrument, Shares Issued

26,247,619

ConvertibleNoteThirteenMember

Debt Conversion, Converted Instrument, Amount

$ 38,000

ConvertibleNoteNineMember

Debt Conversion, Converted Instrument, Shares Issued

14,859,260

ConvertibleNoteFourteenMember

Debt Conversion, Converted Instrument, Amount

$ 38,000

Noteholder

Debt Conversion, Converted Instrument, Shares Issued

146,717,525

Principal | ConvertibleNoteEightMember

Debt Conversion, Converted Instrument, Amount

$ 83,500

$ 53,957

Principal | ConvertibleNoteSevenMember

Debt Conversion, Converted Instrument, Amount

$ 126,000

60,000

Principal | ConvertibleNoteFiveMember

Debt Conversion, Converted Instrument, Amount

$ 240,000

66,000

Principal | ConvertibleNoteTenMember

Debt Conversion, Converted Instrument, Amount

$ 53,000

53,000

Principal | ConvertibleNoteElevenMember

Debt Conversion, Converted Instrument, Amount

$ 33,000

Principal | ConvertibleNoteNineMember

Debt Conversion, Converted Instrument, Amount

$ 53,000

38,000

Principal | 8% Convertible Note

Debt Conversion, Converted Instrument, Amount

$ 75,000

Principal | Noteholder

Debt Conversion, Converted Instrument, Amount

270,957

Accrued interest | ConvertibleNoteEightMember

Debt Conversion, Converted Instrument, Amount

4,600

Accrued interest | ConvertibleNoteSevenMember

Debt Conversion, Converted Instrument, Amount

4,342

Accrued interest | ConvertibleNoteFiveMember

Debt Conversion, Converted Instrument, Amount

4,995

Accrued interest | ConvertibleNoteTenMember

Debt Conversion, Converted Instrument, Amount

2,120

Accrued interest | ConvertibleNoteNineMember

Debt Conversion, Converted Instrument, Amount

2,120

Accrued interest | Noteholder

Debt Conversion, Converted Instrument, Amount

$ 18,177

Note 13 - Concentrations and _2

Note 13 - Concentrations and Credit Risk (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
FDIC	$ 250,000
First Customers [Member] | Sales [Member]
Concentration percentage	24.00%	30.00%
Second Customers [Member] | Sales [Member]
Concentration percentage	17.00%	21.00%
One Customer [Member] | Accounts Receivable [Member]
Concentration percentage	96.00%	100.00%
Third Customer [Member] | Sales [Member]
Concentration percentage	17.00%	21.00%
Fourth Customer [Member] | Sales [Member]
Concentration percentage		19.00%

Note 14 - Related Party Trans_2

Note 14 - Related Party Transactions (Details Narratives) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Disclosure Text Block [Abstract]
Amounts due to related parties	$ 139,753	$ 145,367

Note 15 - Commitments And Con_3

Note 15 - Commitments And Contingencies (Details)	Mar. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
2019	$ 3,380

Note 15 - Commitments and Con_4

Note 15 - Commitments and Contingencies (Details Narratives) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disclosure Text Block [Abstract]
Rent expense	$ 7,728	$ 7,048
Term	3 years
Base Salary	$ 75,000

Note 16- Subsequent Events (Det

Note 16- Subsequent Events (Details Narrative) - USD ($)

May 15, 2019

Jan. 03, 2019

Aug. 13, 2018

May 03, 2018

Mar. 06, 2018

Jan. 10, 2018

Mar. 29, 2019

Feb. 15, 2019

Sep. 17, 2018

Jun. 25, 2018

Mar. 30, 2017

Mar. 31, 2019

ConvertibleNoteTwelveMember

Debt Conversion, Converted Instrument, Amount

$ 38,000

ConvertibleNoteEightMember

Debt Conversion, Converted Instrument, Shares Issued

25,674,344

ConvertibleNoteSevenMember

Debt Conversion, Converted Instrument, Shares Issued

35,446,300

ConvertibleNoteFiveMember

Debt Conversion, Converted Instrument, Shares Issued

44,490,002

ConvertibleNoteTenMember

Debt Conversion, Converted Instrument, Shares Issued

26,247,619

Noteholder

Debt Conversion, Converted Instrument, Shares Issued

146,717,525

Noteholder | Subsequent Event [Member]

Debt Conversion, Converted Instrument, Shares Issued

35,966,371

ConvertibleNoteThirteenMember

Debt Conversion, Converted Instrument, Amount

$ 38,000

ConvertibleNoteNineMember

Debt Conversion, Converted Instrument, Shares Issued

14,859,260

ConvertibleNoteFourteenMember

Debt Conversion, Converted Instrument, Amount

$ 38,000

Principal | ConvertibleNoteEightMember

Debt Conversion, Converted Instrument, Amount

$ 83,500

$ 53,957

Principal | ConvertibleNoteSevenMember

Debt Conversion, Converted Instrument, Amount

$ 126,000

60,000

Principal | ConvertibleNoteFiveMember

Debt Conversion, Converted Instrument, Amount

$ 240,000

66,000

Principal | ConvertibleNoteTenMember

Debt Conversion, Converted Instrument, Amount

$ 53,000

53,000

Principal | Noteholder

Debt Conversion, Converted Instrument, Amount

270,957

Principal | Noteholder | Subsequent Event [Member]

Debt Conversion, Converted Instrument, Amount

$ 55,232

Principal | ConvertibleNoteElevenMember

Debt Conversion, Converted Instrument, Amount

$ 33,000

Principal | ConvertibleNoteNineMember

Debt Conversion, Converted Instrument, Amount

$ 53,000

38,000

Principal | 8% Convertible Note

Debt Conversion, Converted Instrument, Amount

$ 75,000

Accrued interest | ConvertibleNoteEightMember

Debt Conversion, Converted Instrument, Amount

4,600

Accrued interest | ConvertibleNoteSevenMember

Debt Conversion, Converted Instrument, Amount

4,342

Accrued interest | ConvertibleNoteFiveMember

Debt Conversion, Converted Instrument, Amount

4,995

Accrued interest | ConvertibleNoteTenMember

Debt Conversion, Converted Instrument, Amount

2,120

Accrued interest | Noteholder

Debt Conversion, Converted Instrument, Amount

18,177

Accrued interest | Noteholder | Subsequent Event [Member]

Debt Conversion, Converted Instrument, Amount

$ 1,691

Accrued interest | ConvertibleNoteNineMember

Debt Conversion, Converted Instrument, Amount

$ 2,120